How to Safeguard Your mAb Pipeline With Stability Testing

Protein stability issues can jeopardize monoclonal antibody programs, causing regulatory delays or termination. In this case study, learn how orthogonal stability studies exposed vulnerabilities in a developer's mAb molecule, speeding development and enhancing regulatory standing.

Download now to learn more about:

A multi-method approach identified critical degradation pathways missed by a single method
Why early stability assessment avoids costly reformulation and regulatory issues
What analytical techniques offer the most comprehensive mAb stability profile

For these insights and more, download now.

This custom content was created by members of the studioID Expert Network for a sponsor of our publication.

studioID is BioPharma Dive's award-winning content studio. We help brands tell stories that create connections, build trust, and drive demand. Learn how we can help you tell compelling stories and drive ROI. Visit studioID.com

About this email: You are receiving this message as part of your complimentary newsletter subscription to BioPharma Dive. If you no longer wish to receive the daily newsletter, you can switch to a weekly subscription or unsubscribe. See our full privacy policy. BioPharma Dive is a product of TechTarget, Inc. and its subsidiaries, 275 Grove St. Newton, MA 02466